Myogenin

A myogenic regulatory factor that controls myogenesis. Myogenin is induced during differentiation of every skeletal muscle cell line that has been investigated, in contrast to the other myogenic regulatory factors that only appear in certain cell types.

Networked: 510 relevant articles (7 outcomes, 37 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Rekhi, Bharat: 6 articles (06/2022 - 12/2011)
2.	Bridge, Julia A: 6 articles (03/2022 - 09/2002)
3.	López-Calderón, Asunción: 6 articles (05/2021 - 11/2009)
4.	Martín, Ana Isabel: 6 articles (05/2021 - 11/2009)
5.	Parham, David M: 6 articles (03/2021 - 11/2004)
6.	Folpe, Andrew L: 6 articles (01/2021 - 05/2002)
7.	Barr, Frederic G: 6 articles (05/2014 - 12/2002)
8.	Alaggio, Rita: 5 articles (05/2021 - 03/2006)
9.	Teot, Lisa A: 5 articles (05/2014 - 11/2004)
10.	McCluggage, W Glenn: 4 articles (09/2021 - 03/2013)

Related Diseases

1.	Rhabdomyosarcoma 10/01/2018 - "The present study was aimed at evaluating clinicopathologic and immunohistochemical (IHC) features of 300 rhabdomyosarcomas (RMSs), including differential IHC expression and prognostic value of myogenin and MyoD1 across various subtypes of RMSs. " 09/01/2008 - "Rhabdomyosarcoma subtyping by immunohistochemical assessment of myogenin: tissue array study and review of the literature." 02/01/2021 - "Mutant myogenin promoter-controlled oncolytic adenovirus selectively kills PAX3-FOXO1-positive rhabdomyosarcoma cells." 01/01/2021 - "Evaluation of Myogenin and MyoD1 as Immunohistochemical Markers of Canine Rhabdomyosarcoma." 08/01/2016 - "A diagnosis of an adult onset sinonasal rhabdomyosarcoma was made on histopathological examination of the nasal biopsy, supported by immunohistochemistry (IHC) showing strong myogenin positivity, focal positivity for PAX8 and negativity for CK, LCA, S-100 and CD99. "
2.	Neoplasms (Cancer) 09/01/2001 - "Previous studies have focused on expression of myogenin and MyoD1 in small round cell tumors. " 09/01/2000 - "In this study, we evaluated myogenin expression using the monoclonal myf-4 antibody (Novocastra Labs) on FFPE in a large number of pediatric tumors in order to define the clinical utility of this marker. " 05/01/2021 - "Review of the literature identified 160 pediatric benign tumors with skeletal muscle differentiation of which 9 reported myogenin positivity. " 05/01/2021 - "Pediatric Benign Tumors With a Skeletal Muscle Component: Myogenin Expression, Diagnostic Pitfalls, and New Molecular Insights." 12/01/2020 - "Myogenin immunostain must be systematic in case of vaginal polypoid mass, in order to rule out malignancy."
3.	Alveolar Rhabdomyosarcoma 05/01/2021 - "Correction: A human Myogenin promoter modified to be highly active in alveolar rhabdomyosarcoma drives an effective suicide gene therapy." 01/01/2021 - "A human Myogenin promoter modified to be highly active in alveolar rhabdomyosarcoma drives an effective suicide gene therapy." 06/01/2013 - "Compared with ALK-negative alveolar rhabdomyosarcomas, ALK-positive ones are presented with metastatic spread more frequently and showed a greater extent of myogenin reactivity. " 02/27/2014 - "A paradoxical feature of alveolar rhabdomyosarcoma (ARMS), a prevalent soft tissue sarcoma in children arising from cells with a myogenic phenotype, is the inability of these cells to undergo terminal differentiation despite the expression of MYOGENIN. " 01/01/2013 - "However, the recognition of new variants of embryonal rhabdomyosarcoma (ERMS), shifts in the diagnostic criteria of alveolar rhabdomyosarcoma (ARMS), the increasing use of myogenin immunohistochemistry and recognition of the distinct biologic properties associated with fusion status all raised questions about the continued use of this classification system in the diagnosis and treatment of patients with RMS. "
4.	Hyperphosphatemia 12/05/2022 - "Identification of Agents That Ameliorate Hyperphosphatemia-Suppressed Myogenin Expression Involved in the Nrf2/p62 Pathway in C2C12 Skeletal Muscle Cells." 10/11/2023 - "The combination of hypocalcemia with hyperphosphatemia induced a significant reduction (50%) in differentiation marker levels, such as MyoD (protein 1 for myoblast determination) and myogenin on the 1st day of differentiation, and MHC (myosin heavy chains) after 6 days of differentiation compared to control. "
5.	Spinal Muscular Atrophy (Progressive Muscular Atrophy) 07/01/2019 - "Immunohistochemical (IHC) stains were performed using vimentin, myogenin, spinal muscular atrophy, and muscle-specific actin, which all showed positive results. " 10/15/2012 - "Histone deacetylase inhibition suppresses myogenin-dependent atrogene activation in spinal muscular atrophy mice."

Related Drugs and Biologics

1.	Desmin
2.	Antibodies
3.	Vimentin
4.	Myosin Heavy Chains (Myosin Heavy Chain)
5.	Differentiation Antigens
6.	MyoD Protein
7.	Creatine Kinase (Creatine Phosphokinase)
8.	Plant Extracts
9.	Proteins (Proteins, Gene)
10.	Messenger RNA (mRNA)

Related Therapies and Procedures

1.	Lasers (Laser)
2.	Denervation
3.	Resistance Training
4.	Tenotomy
5.	Electroacupuncture